Health News

The hormone deprivation therapy that prostate cancer patients often take gives them only a temporary fix, with tumors usually regaining their hold within a couple of years.

Read more

Filed under: Pharmacy News
Tags: cancer, Pharmacy, Prostate Cancer, Tumor

Related posts

• Study shows delivering cancer drug in hydrophobic nanoparticle is a safe and effective prostate cancer therapy (0)
  Researchers at MIT and Brigham and Women's Hospital have shown that they can deliver the cancer drug cisplatin much more effectively and safely in a form that has been encapsulated in a nanoparticle targeted to prostate tumor cells and is activated once it reaches its target. Read more [tags] Pharmacy News [/tags]
  
  
• Studies demonstrate that investigational cancer vaccines show encouraging immune response rates (0)
  Results of two phase 1 studies demonstrate that the novel, investigational cancer vaccines MKC1106-MT and MKC1106-PP are well-tolerated and show encouraging immune response rates and objective tumor response in advanced melanoma, prostate cancer and other solid malignancies, setting the stage for phase 2 studies. Read more [tags] Pharmacy News [/tags]
  
  
• Scientists study a botanical formula that kills aggressive prostate cancer tumors (0)
  Scientists at Indiana University, Methodist Research Institute study a botanical formula that kills aggressive prostate cancer tumors. Their findings, based on experiments in mice using a human prostate cancer tumor model, appear online in The International Journal of Oncology. Read more [tags] Pharmacy News [/tags]
  
  
• Pervasis’ PVS-30200 study data in prostate cancer presented at AACR meeting (0)
  Pervasis Therapeutics, Inc. today announced preclinical data showing positive effects of PVS-30200, the company's investigational cell therapy for the treatment of solid tumors, on controlling tumor growth and inhibiting metastases in an animal model of prostate cancer. Read more [tags] Pharmacy News [/tags]
  
  
• Merck Serono to present Erbitux data at ESMO Congress (0)
  Merck Serono, a division of Merck KGaA, Darmstadt, Germany announces today that it will be presenting new data from several studies of Erbitux (cetuximab) in a range of solid tumor types including the first Phase II data in breast and prostate cancers. These data will be presented at the forthcoming 35th European Society for Medical [...]